Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies

BJU International

Volumn 92, Issue 3, 2003, Pages 257-261

  Roehrborn, C G ^a   Van Kerrebroeck, P ^b   Nordling, J ^c  

^a Univ of TX S W Medical Center   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

blocker; Alfuzosin; BPH; Pooled analysis; Randomized controlled trial

Indexed keywords

ALFUZOSIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; META ANALYSIS; NOCTURIA; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; URINARY TRACT INFECTION; URINE FLOW RATE; URINE RETENTION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; URINARY RETENTION;

EID: 0042635458     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04309.x     Document Type: Article

References (20)

1. Roehrborn CG, Bartsch G, Kirby R et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 642-50
2. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
3. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001; 58: 508-16
4. Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-61
5. Buzelin JM, Roth S, Geffriaud-Ricouard C et al. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190-8
6. Teillac P, Delauche-Cavallier MC, Attali P. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58-64
7. Lukacs B, Grange JC, Comet D et al. Three-year prospective study of the 3228 BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis 1998; 1: 276-83
8. Buzelin JM, Delauche-Cavallier MC, Roth S et al. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997; 79: 898-906
9. Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169-75
10. McKeage K, Plosker GL. Alfuzosin. A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633-53
11. Roehrborn CG, for the ALFLIS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-9
12. van Kerrebroeck P, Jardin A, Laval KU et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306-13
13. Roehrborn CG, Osterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study. A one-year study of terazosin versus placebo in the treatment of men with benign prostatic hyperplasia. Urology 1996; 47: 159-68
14. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900
15. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15
16. Lepor H, for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901-6
17. Hofner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol 2002; 19: 405-12
18. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther 2000; 17: 287-300
19. Moriyama N, Nasu K, Takeuchi T et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol 1997; 122: 1009-14
20. Giuliano F, Allard J, McKenna et al. Tamsulosin has more deleterious effects than alfuzosin on parameters characterizing ejaculation in anaesthetized rats. Int J Impot Res 2002; 14 (Suppl 3): S12